Therapy with lenalidomide plus dexamethasone-induced bone formation in a patient with refractory multiple myeloma
暂无分享,去创建一个
H. Tsuda | H. Yamasaki | T. Tsuji | Eri Yokoo
[1] G. Roodman,et al. Myeloma bone disease: Pathophysiology and management , 2013, Journal of bone oncology.
[2] M. Dimopoulos,et al. Advances in imaging and the management of myeloma bone disease. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[3] U. Mellqvist,et al. Optimizing the use of lenalidomide in relapsed or refractory multiple myeloma: consensus statement , 2011, Leukemia.
[4] M. Dimopoulos,et al. The use of biochemical markers of bone remodeling in multiple myeloma: a report of the International Myeloma Working Group , 2010, Leukemia.
[5] M. Dimopoulos,et al. Increased bone mineral density in a subset of patients with relapsed multiple myeloma who received the combination of bortezomib, dexamethasone and zoledronic acid. , 2010, Annals of oncology : official journal of the European Society for Medical Oncology.
[6] F. Dammacco,et al. Constitutive down-regulation of Osterix in osteoblasts from myeloma patients: in vitro effect of Bortezomib and Lenalidomide. , 2010, Leukemia research.
[7] H. Asaoku,et al. Osteoprogenitor differentiation is not affected by immunomodulatory thalidomide analogs but is promoted by low bortezomib concentration, while both agents suppress osteoclast differentiation. , 2008, International journal of oncology.
[8] M. Dimopoulos,et al. The effect of novel anti-myeloma agents on bone metabolism of patients with multiple myeloma , 2007, Leukemia.
[9] D. Esseltine,et al. Response to bortezomib is associated to osteoblastic activation in patients with multiple myeloma , 2005, British journal of haematology.
[10] Terry M Therneau,et al. Review of 1027 patients with newly diagnosed multiple myeloma. , 2003, Mayo Clinic proceedings.